ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Clinical trial goes wrong

March 20, 2006 | APPEARED IN VOLUME 84, ISSUE 12

A Phase I clinical trial in the U.K. has left six volunteers in an intensive care unit. Boston-based Parexel was running the trial for TGN 1412, an immunomodulatory monoclonal antibody being developed by the German biopharmaceutical company TeGenero for the treatment of autoimmune/inflammatory diseases and hematooncological malignancies. The trial was the first time the drug was used in humans. "Such an adverse reaction occurs extremely rarely, and this is an unfortunate and unusual situation," says Herman Scholtz, head of Parexel International Clinical Pharmacology. The patients are being treated at Northwick Park Hospital, where the trials were being conducted. The U.K.'s Medicines & Healthcare Products Regulatory Agency has suspended the trials and promises an "exhaustive investigation."

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment